文献速递白血病造血干细胞移植与细胞治疗

靶向FLT3的即用型CAR工程化自然杀伤细胞增强对急性髓系白血病的杀伤作用

Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2023-01-01

研究开发了冻存即用型同种异体人NK细胞,经工程化表达靶向FLT3的CAR并分泌可溶性IL-15(FLT3 CAR_sIL-15 NK)。该细胞对FLT3阳性AML细胞系表现出更高的细胞毒性和干扰素γ分泌,在MOLM-13 AML模型及原位患者来源异种移植AML模型中较对照NK细胞延长生存,且对健康血单核细胞和造血干细胞无细胞毒性。

要点

  • FLT3 CAR_sIL-15 NK细胞对FLT3阳性AML细胞系的细胞毒性和干扰素γ分泌高于缺乏FLT3 CAR或可溶性IL-15的活化NK细胞。
  • 冻存复苏的同种异体FLT3 CAR_sIL-15 NK细胞在MOLM-13 AML模型及原位患者来源异种移植AML模型中较对照NK细胞延长生存。
  • FLT3 CAR_sIL-15 NK细胞对健康血单核细胞或造血干细胞无细胞毒性。

核心结论

  • 数据提示FLT3是AML相关抗原,可被冻存同种异体即用型FLT3 CAR_sIL-15 NK细胞靶向,可能为AML治疗提供新方法。

研究设计与样本

  • 研究开发了冻存即用型同种异体人NK细胞,经工程化表达识别FLT3的CAR并分泌可溶性白细胞介素-15(IL-15)(FLT3 CAR_sIL-15 NK)。

主要发现

  • FLT3 CAR_sIL-15 NK细胞对FLT3阳性AML细胞系的细胞毒性和干扰素γ分泌高于缺乏FLT3 CAR或可溶性IL-15的活化NK细胞。
  • 冻存复苏的同种异体FLT3 CAR_sIL-15 NK细胞在MOLM-13 AML模型及原位患者来源异种移植AML模型中较对照NK细胞延长生存。
  • FLT3 CAR_sIL-15 NK细胞对健康血单核细胞或造血干细胞无细胞毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The majority of patients with acute myeloid leukemia (AML) succumb to the disease or its complications, especially among older patients. Natural killer (NK) cells have been shown to have antileukemic activity in patients with AML; however, to our knowledge, primary NK cells armed with a chimeric antigen receptor (CAR) targeting antigens associated with AML as an "off-the-shelf" product for disease control have not been explored. We developed frozen, off-the-shelf allogeneic human NK cells engineered with a CAR recognizing FLT3 and secreting soluble interleukin-15 (IL-15) (FLT3 CAR_sIL-15 NK) to improve in vivo NK cell persistence and T-cell activation. FLT3 CAR_sIL-15 NK cells had higher cytotoxicity and interferon gamma secretion against FLT3+ AML cell lines when compared with activated NK cells lacking an FLT3 CAR or soluble IL-15. Frozen and thawed allogeneic FLT3 CAR_sIL-15 NK cells prolonged survival of both the MOLM-13 AML model as well as an orthotopic patient-derived xenograft AML model when compared with control NK cells. FLT3 CAR_sIL-15 NK cells showed no cytotoxicity against healthy blood mononuclear cells or hematopoietic stem cells. Collectively, our data suggest that FLT3 is an AML-associated antigen that can be targeted by frozen, allogeneic, off-the-shelf FLT3 CAR_sIL-15 NK cells that may provide a novel approach for the treatment of AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mansour AG, Teng KY, Li Z, et al. Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia. Blood Adv. 2023. PMID: 37379267. doi:10.1182/bloodadvances.2022007405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。